Komori
Fuso Pharmaceutical Industries (4538) · PolicyUpdated for sales of cross-shareholdings

Strategic Shareholdings Held to Maintain and Develop Business Relationships

First written in FY2018. . Latest entry: FY2026.

6entries
9years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2018 – FY20262018: 120182019: 120192020: 020202021: 120212022: 120222023: 020232024: 120242025: 020252026: 12026
Same theme, other companies
Business relationships and sales policy through strategic shareholdingsA theme 618 companies write about · 0 as a headwind · 561 as a tailwind

The whole theme swung hardest in 2019: 18 of 135 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 198 companies compared. The sentences above are computed from all 198.Comparing 200 of the theme's 623 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026Updated for sales of cross-shareholdingsAnnual report

    「(Issues for which the number of shares decreased during the current fiscal year) Number of issues (Issues) Total sale proceeds related to the decrease in the number of shares (¥ million) Unlisted shares 1 88 Shares other than unlisted shares 1 173」

    During the current fiscal year, the Company sold 1 unlisted share issue for ¥88 million and 1 share issue other than an unlisted share issue for ¥173 million. The holdings comprised 5 unlisted issues and 14 listed issues.
  2. FY2024Update on the review and sale of strategic shareholdingsAnnual report

    「During the current fiscal year, following a review of the situation as of the end of December 2023 by the Board of Directors at its meeting held on 30 April 2024, the Company decided to continue holding all issues.」

    The Board of Directors decided to continue holding all issues, while the Company sold 1 listed share issue for stated sale proceeds of ¥84 million.
  3. FY2022Updated cross-shareholding informationAnnual report

    「During the current fiscal year, following a review of the situation as of the end of December 2021 by the Board of Directors at its meeting held on 24 March 2022, the Company decided to continue holding all issues.」

    The Board of Directors reviewed the appropriateness and other aspects of the shareholdings and decided to continue holding all issues. The holdings comprised 6 unlisted issues and 16 listed issues, and the Company acquired 1 unlisted share issue for ¥47 million during the fiscal year.
  4. FY2021Update on the review and reduction of strategic shareholdingsAnnual report

    「During the current fiscal year, following a review of the situation as of the end of December 2020 by the Board of Directors at its meeting held on 24 March 2021, the Company decided to continue holding all issues.」

    The Board of Directors reviewed the appropriateness and other aspects of the shareholdings and decided to continue holding all issues. The Company also sold 2 unlisted share issues, with total sale proceeds and other amounts stated as ¥40 million.
  5. FY2019Details of the holding policy and review processAnnual report

    「The Company seeks sustainable growth and increased corporate value from a medium- to long-term perspective and determines the need to hold shares in business partners and other entities that contribute to its operations based on the nature and scale of the transactions. In accordance with this policy, the Board of Directors reviews the appropriateness of the holdings, share prices, and dividend conditions each fiscal year, assessing the rationale for holding them and the appropriateness of holding each issue. If the need to hold a particular issue diminishes, the Company will dispose of and reduce the holding.」

    The Company has specified its policy of reviewing the rationale for holding strategic shareholdings each fiscal year based on their contribution to business relationships, joint research and development, financial transactions, and other matters, and disposing of or reducing holdings where the need is limited. At fiscal year-end, the Company held 23 issues and acquired 1 unlisted share issue during the fiscal year for reasons including joint research and development.
  6. FY2018First statedAnnual report

    「Investment shares held for purposes other than pure investment Number of issues: 23 Total balance sheet carrying amount: ¥3,212 million」

    The Company held 23 investment shares for purposes other than pure investment, with a total balance sheet carrying amount of ¥3,212 million. The stated purpose for holding individual issues was “maintaining and developing business relationships, etc.”
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Fuso Pharmaceutical Industries yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Strategic Shareholdings Held to Maintain and Develop Business Relationships | Fuso Pharmaceutical Industries,Ltd. (4538) | Komori